A recent breakthrough in nano-bowl supported liposome systems has been achieved through a collaboration between Professor Chao Fang’s team at Shanghai Jiao Tong University School of Medicine and the University at Buffalo, SUNY. Published in Nano Letters, this innovative approach enhances drug loading capacity, stability, and controlled release in liposomal drug delivery. As a global leader in lipid-based nanomedicine, Litchlab is actively driving the industrialization of this cutting-edge technology, accelerating advancements in RNA therapeutics, tumor-targeted therapies, and vaccine delivery.
Traditional liposomal drug delivery systems often face limitations such as low drug loading capacity, poor stability, and difficulty in controlled release. In this latest innovation, researchers have designed nano-bowl supported liposomes (NB-Liposomes), where inorganic nano-bowls act as structural scaffolds to enhance liposome stability, drug encapsulation efficiency, and bioavailability.
Litchlab is actively exploring Nano-Bowl LNP (Lipid Nanoparticle) Hybrid Systems to further optimize drug delivery in key therapeutic areas:
· RNA Therapeutics: Enhancing mRNA and siRNA delivery for improved transfection efficiency
· Tumor-Targeted Therapy: Increasing drug accumulation in tumors for improved efficacy
· Vaccine Delivery: Improving antigen presentation and immune response
· Poorly Soluble Small Molecules: Enhancing solubility and bioavailability
Key Features | Litchlab Solution | Application Areas |
Nano-Bowl Structural Support | Enhances liposome stability through inorganic scaffolding | RNA drugs, oncology therapeutics |
High Drug Loading Capacity | Improves encapsulation of small molecules and biologics | Poorly soluble drugs, vaccines |
Controlled Drug Release | Optimized release kinetics for sustained therapeutic effects | Targeted therapies, chronic disease management |
Enhanced Circulation Stability | PEGylation and carrier optimization for extended circulation half-life | Long-acting RNA drugs, monoclonal antibodies |
Tumor-Targeted Delivery | Functionalized liposomes with antibodies or aptamers for precise targeting | Immunotherapy, personalized medicine |
As a leading innovator in liposomal drug delivery, Litchlab provides an end-to-end solution from lab-scale research to GMP manufacturing, accelerating the translation of novel therapeutics:
1. Nano-Liposome Platform Development: From formulation screening to lipid optimization for enhanced RNA drug delivery
2. Scalable Manufacturing Technologies: Microfluidics, high-pressure extrusion, and GMP-compliant production
3. Targeted Functionalization: Antibody and aptamer modifications for improved targeting efficiency
4. Stability Optimization: Increased stability for RNA drugs, monoclonal antibodies, and biologics
5. Precise Size Control: Tailored nanoparticle size (50-200nm) for optimized tissue penetration
The advent of nano-bowl supported liposome systems marks a new era of high-efficiency, precision-targeted drug delivery. Litchlab is partnering with global pharmaceutical leaders to translate this breakthrough technology into clinical-ready nanomedicine solutions, accelerating advancements in RNA therapeutics, oncology, and vaccine development.
For more information, please feel free to contact us at:
E-Mail:RD2@Litchlab.com
